Skip to main content

Refractory Osteosarcoma clinical trials at UCSF

10 in progress, 1 open to eligible people

Refractory osteosarcoma is bone cancer that does not respond to standard treatment. UCSF is running an early-stage study of a drug called tegavivint to find safe doses and record side effects. UCSF is testing treatments for tumors that return or keep growing.

Showing trials for

Our lead scientists for Refractory Osteosarcoma research studies include .

Last updated: